Cholangitis

A year of treatment with Chemomab Therapeutics’s candidate nebokitug reduces key disease biomarkers and the occurrence of clinical events that reflect disease progression among…

Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi…

A Phase 1b/2 trial testing Umecrine Cognition’s golexanolone in primary biliary cholangitis (PBC) patients with cognitive symptoms and fatigue has been delayed due to…

Conscience, a Canadian nonprofit, has awarded CA$461,241 (nearly $320,000) to a research project aiming to provide preclinical data that could lead to new approaches…

“I can’t explain why, but I don’t feel well,” my younger brother, Osari, said. He was 32 years old at the time. That statement was…

Chemomab Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on the best path toward regulatory approval of its investigational therapy nebokitug,…

Gilead Sciences’ oral therapy seladelpar has been conditionally approved by the European Commission as a second-line therapy for adults with primary biliary…

A second liver transplant results in transplant and patient outcomes in people with primary sclerosing cholangitis (PSC) that are comparable or better than those…

Four weeks of treatment with vancomycin, a common antibiotic, lowered  inflammatory bowel disease (IBD) in people with primary sclerosing cholangitis (PSC), data from a…

Testing positive for the self-reactive anti-gp210 and anti-centromeric antibodies significantly increases the risk of poor liver-related outcomes for people with primary biliary cholangitis (PBC),…